Indian drugmakers need more FDA approvals to maintain growth

02/16/2009 | Business Standard (India)

Indian pharmaceutical companies including Dr. Reddy's Laboratories and Sun Pharma would require at least 12 to 14 FDA approvals to achieve their 20% sales growth target in the U.S., according to a Credit Suisse report. Ranbaxy Laboratories, which is under investigation for manufacturing violations, needs 20 more approvals to hit the target this year, the report said.

View Full Article in:

Business Standard (India)

Published in Brief:

SmartBrief Job Listings for Health Care